Skip to main content
. 2017 Apr 17;19(10):1316–1326. doi: 10.1093/neuonc/nox070

Fig. 4.

Fig. 4

Treatment with DEX delays GBMSC accumulation in lesioned areas, but does not prevent it. (A) Representative in vivo MPLSM 3D images of mice implanted with S24 GBMSCs and treated with vehicle control vs DEX (0.3 mg/kg s.c.). Note the decreased formation of a new tumor mass in the lesioned area (dotted circle) at day 7, but similar tumor formations at day 14, 42–195 µm depth under the brain surface. (B) Tumor cell densities in relation to the lesioned area in control vs DEX treated mice on day 5 (left panel), day 7 (middle panel), and day 14 (right panel) postsurgery (43–1653 GBMSCs quantified; 4 regions, n = 3 mice per group, t-test). Error bars show SEM. *P < 0.05.